Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $4.05
Previous CloseN/A
Volume917.00
Average Volume (3M)18.77K
Market Cap
$344.18M
Enterprise Value$91.47M
Total Cash (Recent Filing)€24.87M
Total Debt (Recent Filing)€627.60K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Sep 25, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding95,662,390
10 Day Avg. Volume22,756
30 Day Avg. Volume18,774
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.81
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.67Price Target Upside262.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Inventiva News
---
Bulls Say, Bears Say
Bulls Say
Financial SupportInventiva received additional €126M in funding, providing a cash runway through Q3 2026.
Regulatory ProgressLanifibranor could become the next oral therapy to market if successful, potentially gaining approval in the MASH landscape.
Trial EnrollmentInventiva has completed enrollment of the NATiV3 trial, setting the stage for a definitive topline readout and meeting the requirements to access the second tranche of financing.
Bears Say
Dependence On OutcomeCompletion of the NATiV3 trial enrollment satisfies conditions related to the €116M second tranche of the €348M structured financing, providing financial support for the company's operations.
Trial UncertaintyThe enrichment of T2D patients in the study could prove critical to eliciting the maximum effect in the pivotal data set.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.01% Other Institutional Investors
94.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $4.05 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $344.18M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 25, 2025 which is in 152 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 26, 2025. The company reported -$1.818 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$1.259.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.73.
How many shares outstanding does Inventiva have?
Inventiva has 95,662,390 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.818 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
---
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.67 (262.60% Upside)
$13.67 (262.60% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 36.9%
Last 30 Days ▲ 36.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.10%
12-Months-Change
Fundamentals
Return on Equity
344.74%
Trailing 12-Months
Asset Growth
60.83%
Trailing 12-Months
Company Description
Inventiva
Inventiva (IVA) is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS), and other fibrotic diseases. The company leverages its advanced research and development platform to target key biological pathways involved in fibrosis and inflammation, with its lead product candidate, lanifibranor, currently in advanced-stage clinical trials.
---
IVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of lanifibranor, positive trial results, and a strong financial position bolstered by recent financing activities. However, challenges such as workforce reduction and decreased revenue were noted. The sentiment remains cautiously optimistic with strategic partnerships and governance strengthening, despite financial and operational challenges.Read More>---
IVA Stock 12 Month Forecast
Average Price Target
$13.67
▲(262.60% Upside)
Technical Analysis
Oruka Therapeutics
―
Heron Therapeutics
―
RegenXBio
―
Verve Therapeutics
―
Entrada Therapeutics Inc
―
Best Analysts Covering IVA
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+10.68%
reiterated a buy rating 25 days ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +10.68% per trade.
---